The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Nektar Therapeutics

Nasdaq: NKTR
Last

(U.S.) $16.71

Today's change+0.78 +4.90%
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.
 

Nektar Therapeutics

Nasdaq: NKTR
Last

(U.S.) $16.71

Today's change+0.78 +4.90%
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.

Nektar Therapeutics Hits New 52-week High

Nektar Therapeutics closed up sharply Wednesday, rallying (U.S.)$0.78 or 4.90% to (U.S.)$16.71 and setting a new 52-week high. Over the last five days, shares have gained 21.44% and 47.22% year to date. Shares have outperformed the S&P 500 by 27.15% during the last year.

Key company metrics

  • Open(U.S.) $15.70
  • Previous close(U.S.) $15.93
  • High(U.S.) $16.76
  • Low(U.S.) $15.61
  • Bid / Ask-- / --
  • YTD % change+47.22%
  • Volume2,945,596
  • Average volume (10-day)1,414,748
  • Average volume (1-month)1,185,497
  • Average volume (3-month)1,330,408
  • 52-week range(U.S.) $10.10 to (U.S.) $16.76
  • Beta1.47
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.51
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-26.33%

Nektar Therapeutics has a net profit margin of -26.33%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.23%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue133292031
Total other revenue--------
Total revenue133292031
Gross profit124231222
Total cost of revenue9589
Total operating expense53515667
Selling / general / administrative9101010
Research & development34373848
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)------0
Other operating expenses, total--------
Operating income80-23-36-36
Interest income (expense), net non-operating-10-10-10-10
Gain (loss) on sale of assets--------
Other--------
Income before tax71-32-46-46
Income after tax71-33-46-48
Income tax, total0002
Net income71-33-46-48
Total adjustments to net income--------
Net income before extra. items71-33-46-48
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items71-33-46-48
Inc. avail. to common incl. extra. items71-33-46-48
Diluted net income71-33-46-48
Dilution adjustment----00
Diluted weighted average shares132127124116
Diluted EPS excluding extraordinary itemsvalue per share0.53-0.26-0.37-0.41
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share0.53-0.26-0.37-0.41